A Phase 1/2 Study of Sotorasib and Trastuzumab Deruxtecan in KRAS G12C Mutated NSCLC

Study Description

A Study Testing the Combination of Sotorasib and Trastuzumab Deruxtecan in Treating Locally Advanced or Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation

Study Details

Registry ID:

NCT07012031

Conditions:

Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8

Phase:

Phase 1,Phase 2

Target Enrollment:

37 participants

Start Date:

June 17, 2026

Age Range:

18–999 years

Healthy Volunteers:

No

Study Locations (11 sites)

• Moffitt Cancer Center at Wesley Chapel
  Wesley Chapel, FloridaUnited States, United States
• Moffitt Cancer Center-International Plaza
  Tampa, FloridaUnited States, United States
• Moffitt Cancer Center - McKinley Campus
  Tampa, FloridaUnited States, United States
• Moffitt Cancer Center
  Tampa, FloridaUnited States, United States
• University of Virginia Cancer Center
  Charlottesville, VirginiaUnited States, United States
• University of Pittsburgh Cancer Institute (UPCI)
  Pittsburgh, PennsylvaniaUnited States, United States
• UPMC Hillman Cancer Center
  Pittsburgh, PennsylvaniaUnited States, United States
• University Health Network Princess Margaret Cancer Center LAO
  Toronto, OntarioCanada, Canada
• Case Western Reserve University
  Cleveland, OhioUnited States, United States
• Ohio State University Comprehensive Cancer Center
  Columbus, OhioUnited States, United States
• University of California Davis Comprehensive Cancer Center
  Sacramento, CaliforniaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →